Enhancing response rates to chemotherapy in esophageal cancer with intratumoral administration of the small-molecule surviving inhibitor YM155.
Active Project Grant Awarded Last action
- Award ID
- HT94252410918
- Recipient
-
Vistar Inc. UEI FL46WJ3CAQT4
- Awarding agency
-
Defense Health Agency
Department of Defense
- Obligated
- $110,000
Award facts
- Assistance listing
- 12.420 Military Medical Research and Development
- Completion date 98% complete
- Place of performance
- Birmingham, AL 35233, USA
Award details come from USAspending.gov.
About this award
This $110,000 federal project grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) is funding research conducted by Vistar Inc., doing business as Birmingham VA Hospital, to enhance response rates to chemotherapy in esophageal cancer. The project involves the intratumoral administration of a small-molecule survivin inhibitor (YM155) to improve outcomes for esophageal cancer patients undergoing chemotherapy. The research, which will take place from November 1, 2024 to October 31, 2026, aims to advance medical understanding and treatment in this critical oncology area.
Quick answers
Who received award HT94252410918?
HT94252410918 was awarded to Vistar Inc. by Defense Health Agency (Department of Defense) on November 1, 2024.
How much is award HT94252410918 worth?
$110,000 has been obligated on HT94252410918.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award